| Document |
Document Title |
|
WO/2006/127893A2 |
The present invention relates to processes for the production of 4-(biphenylyl)azetidin-2-one phosphonic acid derivatives of formula.
|
|
WO/2006/122117A2 |
The invention relates to chemical genera of organometal benzenephosphonates useful in cross-coupling organic synthesis, having general formula (I): where R is selected from boron, zinc, tin and silicon residues.
|
|
WO/2006/121708A1 |
Disclosed herein is the use of compounds of Formula (I) wherein Y, A and D are described herein or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof for the treatment of inflammatory bowel disease and of glaucoma.
|
|
WO/2006/122020A2 |
The present invention relates to processes for the production of 4-biphenylylazetidin-2-one derivatives of formula (I).
|
|
WO/2006/118307A1 |
A therapeutic agent for pains characterized by containing as an active ingredient at least one of a compound represented by the following formula (I): [Chemical formula 1] (I) [wherein A is L-W (L is a bond or methylene and W is -NR7- (R...
|
|
WO/2006/102674A2 |
Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivative are described, as are pharmaceutical compositions containing these compound and their use for preparing medicaments for the treatment of hypercholesterolemia
|
|
WO/2006/095020A1 |
Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1, have renin-inhibiting properties and can be used as medicines.
|
|
WO/2006/093352A1 |
A compound represented by the general formula (1') or a salt thereof: (1') wherein R represents an aldopyranose residue, R2 represents a hydrocarbon group having 2 to 18 carbon atoms which may have a substituent; R3 represents an acyl gr...
|
|
WO/2006/090153A1 |
A process for preparing a protected amidine group of formula (I): wherein R6 represents, for example, C1-10 alkyl (optionally substituted), aryl, C1-3 alkylaryl or C1-3 alkyloxyaryl; which comprises reacting a nitrile containing compound...
|
|
WO/2006/077026A1 |
The present invention relates to compounds of the general formula (I) wherein R1 is -OR1 , -SR1 or is a heterocycloalkyl group; R1 is lower alkyl, lower alkyl substituted by halogen, or is -(CH2)n-cycloalkyl; R2 is -S(O)2-lower alkyl or ...
|
|
WO/2006/068990A1 |
A process is provided for preparing azetidinones useful as intermediates in the synthesis of penems and as hypocholesterolemic agents, comprising reacting a ß-(substituted-amino)amide, a ß-(substituted-amino)acid ester, or a ß-(substi...
|
|
WO/2006/064757A1 |
A compound represented by the general formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug of any of these; and a drug containing any of these. (I) (In the formula, all the symbols are as defined in the d...
|
|
WO/2006/060808A1 |
Provided are processes for preparing crystalline forms of ezetimibe, such as ezetimibe Form A or Form B, for example, by precipitating ezetimibe from selected solvents. Alternatively, some forms may be transformed into different forms at...
|
|
WO/2006/060225A2 |
Processes for asymmetric synthesis of 1O(S)-amino-3-hydroxy-4-oxo-4,6,7,8,9,10hexahydropyrimido[
1,2-a]azepine-2-carboxamides and related compounds are disclosed. The enantiomerically enriched carboxamides are useful as HIV integrase i...
|
|
WO/2006/056696A2 |
2-alcoxy-3,4,5-trihydroxy-alkylamides, the preparation thereof, compositions containing them and use thereof. The invention relates particularly to 2-alcoxy-3,4,5-trihydroxy-alkylamides, the preparation thereof, compositions containing t...
|
|
WO/2006/050634A1 |
An improved process for producing 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxyprop
yl]-(4S)-(4-hydroxyphenyl)-2-azetidinone, comprising: cyclizing the β-(substituted-amino)amide of formula (I) in the presence of a inert orga...
|
|
WO/2006/049113A1 |
A compound (I) which is obtained by the following reaction scheme: (II) (III) (IV) (V) (I) (wherein R1 and R2 represent a protecting group for a hydroxy group and a protecting group for a carboxy group, respectively, and X represents a h...
|
|
WO/2006/040464A1 |
The invention relates to a novel method for the synthesis of N-{1-[bis-(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-diflu
orophenyl)-methylsulphonamide.
|
|
WO/2006/040182A1 |
The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated...
|
|
WO/2006/034277A1 |
The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer’s disease.
|
|
WO2005063239A9 |
The invention relates to amid compounds of general formula (I), wherein groups and residuals A, B, b, W, X, Y, Z, R
|
|
WO/2006/021806A1 |
Compounds of formula (I) are useful in treatment of sleep disorders and other conditions mediated by 5-HT2A receptor activity.
|
|
WO/2006/021805A1 |
Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
|
|
WO/2006/015854A2 |
Compounds of formula (I) in free or salt form, wherein Ar, X, Y and T have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as ...
|
|
WO/2005/117865A1 |
The present invention relates to compounds of formula (I) wherein A, R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositi...
|
|
WO/2005/118544A2 |
The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseas...
|
|
WO/2005/116027A2 |
The present invention provides for compounds of formula (I), which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention ...
|
|
WO/2005/115975A1 |
Arylalkylamines represented by the general formula (I) or pharmacologically acceptable salts thereof; a process for the production of the compounds, use of the compounds as activator for Ca-sensitive receptors, i.e., as CaSR agonist, and...
|
|
WO/2005/113496A1 |
The invention relates to a method for producing 1,4-diphenyl azetidinone derivatives from suitably protected $g(b)-substituted amino amides, in the presence of silylation agents. Said method uses cyclization catalysts that comprise phosp...
|
|
WO/2005/113495A1 |
The invention relates to a method for producing diphenyl azetidinone derivatives of general formula (I) or forms protected in the substituents X, R1 and/or R2, wherein the symbols, substituents, and indices have the following designation...
|
|
WO/2005/110983A1 |
The present invention is directed to azetidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmi...
|
|
WO2004113297A9 |
This invention relates to novel aza-dng dedvatives useful as monoamine neurotransmifter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions...
|
|
WO/2005/108357A1 |
The invention provides highly functionalised spiro-fused lactams of formula (I) having a cyclohexane moiety with the desired number of protected or unprotected functional groups or carbonated structures, which are introduced with high st...
|
|
WO/2005/108356A1 |
New spirolactams of formula (I) having a cycloexadienone moiety which are highly stable due to pi interactions between the W group and the dienone moiety. They are useful as UV absorbers and as intermediates for the synthesis of active b...
|
|
WO/2005/103001A1 |
The invention relates to the phenyl acetamides of formula (I), to a method for producing them and to their use for producing drugs for use in the treatment and/or prophylaxis of human or animal diseases, especially cardiovascular diseases.
|
|
WO/2005/100325A1 |
Compounds of the following Formula (I) wherein R1 and R2 are independently selected from alkyl or alkenyl or from a heterocyclic ring together with the N to which they are bound, n is 0-2, Ar1 is (substituted) phenyl and Ar1 is (substitu...
|
|
WO/2005/100308A1 |
The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl ace...
|
|
WO/2005/095343A1 |
The invention relates to compounds of formula (I), Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7), wherein Z, R1-7 and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention als...
|
|
WO/2005/089759A1 |
The invention relates to a compound having general formula (I), wherein: m = 1 to 4; n represents = 1, 2 or 3; o = 1 or 2; A is selected from among one or more X, Y and/or Z groups; X = optionally-substituted methylene; Y = C2-alkenylene...
|
|
WO/2005/087215A1 |
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of d...
|
|
WO/2005/082841A1 |
The present invention relates to immunosuppressants, processes for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of d...
|
|
WO/2005/080376A1 |
The present application describes modulators of CCR3 of formula (Ia) and (Ib): (I) or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5', R6, a, b, c, d, and u are as defined herein. In addition, methods o...
|
|
WO/2005/077896A1 |
The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of ...
|
|
WO/2005/077899A2 |
Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y1 and Y2 form various tricyclic cores, Xa and Xb are C, CH, or N, as defined herein, and Rx is an optional substituent. Compounds and compositions of formula (I)...
|
|
WO/2005/077463A2 |
One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapeutically effective amount of a heterocyclic c...
|
|
WO/2005/077897A1 |
The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of ...
|
|
WO/2005/070877A1 |
The application relates to novel amino alcohols of the general formula (I) where R, R1, R2, R3, R4, R5 and R6 each have the definitions illustrated in detail in the description, to a process for their preparation, and to the use of these...
|
|
WO/2005/066120A2 |
Provided herein are processes for asymmetric synthesis of hydroxyalkyl-substituted azetidinone derivatives or intermediates thereof via stereoselective reduction of benzylic ketone using (-)-B-chlorodiisopinocampheylborane. Also provided...
|
|
WO/2005/062897A2 |
The present invention relates to novel crystalline forms and amorphous form of Ezetimibe and the processes for the preparation thereof.
|
|
WO/2005/063704A1 |
It is intended to provide compounds having EDG-5 antagonism. Because of having EDG-5 antagonism, compounds represented by the following general formula (I): (I) wherein each symbol is as defined in the description; salts thereof, N-oxide...
|
